Compare · ILMN vs RDNT
ILMN vs RDNT
Side-by-side comparison of Illumina Inc. (ILMN) and RadNet Inc. (RDNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and RDNT operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $24.21B, about 5.5x RDNT ($4.42B).
- Over the past year, ILMN is up 81.8% and RDNT is down 5.3% - ILMN leads by 87.1 points.
- ILMN has been more active in the news (23 items in the past 4 weeks vs 9 for RDNT).
- ILMN has more recent analyst coverage (25 ratings vs 10 for RDNT).
- Company
- Illumina Inc.
- RadNet Inc.
- Price
- $160.01+1.19%
- $56.18+3.65%
- Market cap
- $24.21B
- $4.42B
- 1M return
- +12.73%
- -3.49%
- 1Y return
- +81.81%
- -5.26%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 23
- 9
- Recent ratings
- 25
- 10
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
RadNet Inc.
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.
Latest ILMN
- SVP, Chief People Officer Leckman Patricia sold $127,305 worth of shares (783 units at $162.59), decreasing direct ownership by 4% to 21,259 units (SEC Form 4)
- Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
Latest RDNT
- RadNet Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Swartz David L was granted 2,946 shares, increasing direct ownership by 2% to 179,712 units (SEC Form 4)
- Director Spurlock Gregory E. was granted 2,946 shares, increasing direct ownership by 56% to 8,236 units (SEC Form 4)
- Director Jacobs Laura Pastre was granted 2,946 shares, increasing direct ownership by 11% to 29,953 units (SEC Form 4)
- Director Levitt Lawrence L was granted 2,946 shares, increasing direct ownership by 2% to 167,902 units (SEC Form 4)
- RadNet Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities
- RadNet to Host Men's Health Webinar on June 13, 2026
- Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts
- SEC Form SCHEDULE 13G filed by RadNet Inc.